Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japanese Biotechs Promote "Relationship Building" In Developing Marketing Deals

This article was originally published in PharmAsia News

Executive Summary

Building solid relationships with licensing partners is key to sustaining and expanding those alliances in the long term, Eisai VP-Business Development Alex Scott said during a May 8 panel discussion at the Biotechnology Industry Organization International Convention in Boston

You may also be interested in...

Eisai Enters Biologics Arena With $325 Million Morphotek Acquisition

Japanese firm plans to grow U.S. sales to $4 billion via expanded sales force of 1,500 by 2011, Eisai tells “The Pink Sheet” DAILY.

Astellas VP-Business Development Masaki Doi: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Japanese pharma exec discusses Astellas’ global licensing strategy, the FibroGen deal, and the changing paradigm of Japanese deal flow.

Japanese Mergers Provide Opening For Biotech Deals – Novartis Licensing Head

But multinationals may be increasingly squeezed out of Japanese deals due to the merger wave, company exec tells BIO-Asia conference in Tokyo.

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts